Fresenius Medical Care AG & Co. KGaA
HealthcareNYSE:FMS · New York Stock Exchange
+$0.66 today
Vol 0.47M · Avg 0.77M
Management
Put operating results in leadership context
Review returns on capital, executive background, insider transactions, and growth quality to judge whether management is compounding value well.
Return Metrics
ROE, ROIC & ROA over time
ROE
6.8%
avg 9.0%
ROIC
5.3%
avg 6.2%
ROA
3.2%
avg 3.6%
Analysis
ROE is currently the strongest return metric at 6.8% versus its period average of 9.0%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Tenure | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|---|
Helen Giza | Chair of Management Board & Chief Executive Officer | $4.34M | — | 58 | — | — |
Craig Cordola FACHE | Chief Executive Officer of Care Delivery & Member of Management Board | $3.74M | — | 54 | — | — |
Joseph E. Turk Jr. | Chief Executive Officer of Care Enablement & Member of Management Board | $3.71M | — | 58 | — | — |
Charles Hugh-Jones | Global Chief Medical Officer & Member of Management Board | $3.12M | — | 56 | — | — |
Martin Fischer | Chief Financial Officer & Member of the Management Board | $2.51M | — | 48 | — | — |
Jorg Haring | Member of the Management Board, Global Head of Legal,Compliance & Human Resources and Labor Director | $1.90M | — | 56 | — | — |
Dominik Heger | Executive Vice President and Head of Investor Relations, Strategic Development & Communications | — | — | — | — | — |
Gail-Suzanne Brown | Senior Vice President of Research & Development | — | — | — | — | — |
Glenn Slater | Senior Vice President of Manufacturing and Supply Chain Operations | — | — | — | — | — |
Joachim Weith | Senior Vice President of Corporate Communications & Governmental Affairs | — | — | — | — | — |
Insider Trading
SEC Form 4 transactions — last 12 months
No insider transactions in the last 12 months.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | +2.2% | +4.9% (15yr)2 analysts |
| Revenue | N/A | N/A | +13.6% | +2.8% (15yr)4 analysts |
| Net Income | N/A | N/A | +1.6% | +4.7% (15yr)4 analysts |
| EBIT | N/A | N/A | +8.3% | -0.3% (15yr)4 analysts |
Analysis
Recent growth has been strongest in Revenue at +13.6% over three years. Forward estimates point to EPS at +4.9% (15yr), giving you a quick check on whether expectations are accelerating or cooling.
Competitors
Peer companies in the same sector
Royalty Pharma plc
NASDAQ:RPRX
$23.71B
Hologic, Inc.
HOLX
$16.97B
Tenet Healthcare Corporation
NYSE:THC
$15.15B
Solventum Corporation
NYSE:SOLV
$13.53B
DaVita Inc.
NYSE:DVA
$13.46B
Smith & Nephew plc
NYSE:SNN
$12.97B
ICON Public Limited Company
NASDAQ:ICLR
$11.16B
Encompass Health Corporation
NYSE:EHC
$10.07B
Universal Health Services, Inc.
NYSE:UHS
$9.18B
Tempus AI, Inc.
NASDAQ:TEM
$8.29B
Who manages FMS?
Fresenius Medical Care AG & Co. KGaA (FMS) lists 10 active executives. The top listed executive is Charles Hugh-Jones, Global Chief Medical Officer & Member of Management Board.
Are FMS insiders buying or selling?
Recent insider activity shows net buying of $0.00.
Explore More
Continue the stock analysis
Jump to another research area for this company.